Condition: Leukemia, Myeloid, Acute · Myelodysplastic Neoplasms · Sponsor: Janssen Research & Development, LLC
The purpose of Part 1 (Dose Escalation) of the study is to assess the effective dose (recommended Phase 2 dose\[s\] \[RP2Ds\]) that can be safely administered, and dosing regimens of JNJ-90189892 in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) or R/R higher-risk type of myelodysplastic neoplasms (MDS \[type of cancer of the blood and bone marrow, which does not respond to treatment or comes back after treatment\]). The purpose of Part 2 (Cohort Expansion) is to further assess the safety, tolerability and efficacy in participants with R/R AML or higher-risk types of MDS at the RP2D regimen(s). The purpose of Part 3 and 4 is to assess the effective dose (recommended Phase 2 combination dose \[RP2CD\]) that can be safely administered, and dosing regimens of JNJ-90189892 in combination with azacitadine (AZA) + venetoclax (VEN) in participants with R/R AML (part 3) and newly diagnosed (ND) AML (part 4).
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| Concord Hospital | Concord, Australia | Recruiting |
| Peter MacCallum Cancer Centre | Melbourne, Australia | Recruiting |
| Sir Charles Gairdner Hospital | Nedlands, Australia | Recruiting |
| Institut Paoli-Calmettes | Marseille, France | Recruiting |
| CHRU de Strasbourg - Hopital de Hautepierre | Strasbourg, France | Recruiting |
| Institut Claudius Regaud | Toulouse, France | Recruiting |
| Hosp Univ Fund Jimenez Diaz | Madrid, Spain | Recruiting |
| Clinica Univ. de Navarra | Pamplona, Spain | Recruiting |
| Hospital Universitario Virgen Rocio | Seville, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06651229